Connect with us

Life Sciences

Topcon Screen and AEYE Health Announce Partnership to Enhance Diabetic Retinopathy Screening

AEYE Health, the leader in artificial intelligence-based diagnostics for retinal imaging, and Topcon Screen, a leader in point-of-care diabetic eye exams,…

Published

on

This article was originally published by AITHORITY
Topcon Screen and AEYE Health Announce Partnership to Enhance Diabetic Retinopathy Screening

AEYE Health, the leader in artificial intelligence-based diagnostics for retinal imaging, and Topcon Screen, a leader in point-of-care diabetic eye exams, today announced a partnership to deliver point-of-care screening for diabetic retinopathy that uses AI to produce immediate and accurate results.

AEYE Health’s diagnostic screening technology (AEYE-DS) features best-in-class efficacy and the fastest screening times as it requires only one image per eye and takes less than 5 seconds to process an exam.

Recommended: AiThority Interview with Natalie Schwartz, Head of Global Brand Marketing and Partnerships at Canva

Through this partnership, primary care providers can close care gaps by screening their patients for diabetic retinopathy directly in their clinic, minimizing the risk of non-compliance. To perform the procedure, any healthcare provider staff can obtain one image from each eye using Topcon Healthcare’s fully automatic and robotic TRC-NW400 non-mydriatic retinal camera and have the images instantly diagnosed for diabetic retinopathy using AEYE-DS technology. In an FDA clinical study for the detection of more-than-mild diabetic retinopathy (clearance K221183), AEYE-DS was found to have 93% sensitivity and 91.4% specificity using one image per eye captured by the Topcon NW400 fundus camera.

“We are pleased to partner with AEYE Health to allow our customers to get instant diagnostic results using its best-in-class artificial intelligence technology. The automation and ease-of-use of our TRC-NW400 non-mydriatic retinal camera combined with instant and accurate diagnosis provided by AEYE will make it easier for primary care providers to adopt point-of-care diabetic testing for diabetic retinopathy,” said Therese Nappier, Director of Topcon Screen. “Requiring only a single image per eye means that screening requires even less work and takes less time to perform, which is a critical factor for primary care providers.”

 AIThority News: Core BTS Announces New AI Consulting Services to Help Clients Accelerate use of GenAI Technologies

“I am confident that joining forces with an industry leader like Topcon Screen will help accelerate the adoption of point-of-care diabetic eye exam and help providers close stubborn care gaps related to diabetic retinopathy screening,” said Zack Dvey-Aharon, Ph.D., Co-Founder & CEO of AEYE Health. “The engineering work we put in to enable our AI to deliver instant, best-in-class diagnostic accuracy with best-in-class usability using only a single image per eye will help Topcon transform Topcon’s retinal cameras into instant diagnostic screening devices.”

 AIThority News: New Slack Innovations and Salesforce Customer 360 Integrations Unlock Team Productivity, Adding Value to the Digital HQ

[To share your insights with us, please write to sghosh@martechseries.com]

The post Topcon Screen and AEYE Health Announce Partnership to Enhance Diabetic Retinopathy Screening appeared first on AiThority.

diagnostics




devices
artificial intelligence

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending